SEC ownership of Alvotech

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001898416.

Comparable stake leader

Aztiq Pharma Partners S.a r.l.

Disclosed value leader

Aztiq Pharma Partners S.a r.l.

Comparable rows

50/50

Latest evidence

31 Mar 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 2 signals
Latest 13D/G holder
Aztiq Pharma Partners S.a r.l.
Latest parsed ownership date
31 Mar 2026
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001898416
Issuer location
Luxembourg, Luxembourg

Ownership snapshot

Top shareholders of Alvotech (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Aztiq Pharma Partners S.a...
Disclosed value leader
Aztiq Pharma Partners S.a...
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G 13F Lead comparable stake: 33% 13D/G row: Aztiq Pharma Partners S.a r.l. Showing 1-8 of 50 holder rows.

Quick read

Aztiq Pharma Partners S.a r.l. leads the comparable SEC ownership view at 33%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Aztiq Pharma Partners S.a r.l.'s linked filing trail.
Comparable ownership Top 5
Aztiq Pharma Partners S.a r.l. 33%
VANGUARD CAPITAL MANAGEMENT LLC 1.1%
Bracebridge Capital, LLC 0.87%
MILLENNIUM MANAGEMENT LLC 0.68%
PRICE T ROWE ASSOCIATES INC /MD/ 0.45%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Aztiq Pharma Partners S.a r.l.
13D/G
33%
$533,786,019
103,849,420 shares
$0 17 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
1.1%
$11,834,251
3,410,447 shares
31 Mar 2026
Bracebridge Capital, LLC
13F
Company
13F
0.87%
$9,279,193
2,705,304 shares
31 Mar 2026
MILLENNIUM MANAGEMENT LLC
13F
Company
13F
0.68%
$7,280,504
2,122,596 shares
31 Mar 2026
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
0.45%
$4,793,000
1,397,107 shares
31 Mar 2026
LITTLEJOHN & CO LLC
13F
Company
13F
0.42%
$4,522,572
1,318,534 shares
31 Mar 2026
BlackRock, Inc.
13F
Company
13F
0.4%
$4,271,019
1,245,195 shares
31 Mar 2026
VANGUARD FIDUCIARY TRUST CO
13F
Company
13F
0.31%
$3,380,571
974,228 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Recent insider transactions for Alvotech

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
No insider transactions were found in the last 12 months for this issuer.
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .